Good morning, ladies and gentlemen. It's very good to see everybody here this morning.
Today we are going to be listening to witnesses from the area of pharmaceutical products, prescription and non-prescription, on the post-market surveillance.
We have two orders of business to deal with at the end of the meeting. The first is the motion by Ms. Judy Wasylycia-Leis, and we will deal with that at 12:45. We have another piece of business as well. But seeing as our witnesses are here this morning, we want to make very good use of their expertise and time, and very good use of the time the committee has to ask them questions.
Pursuant to Standing Order 108(2), I'd like to welcome you to the fourth meeting on post-market surveillance of pharmaceutical products, prescription and non-prescription. We have pharmacy professionals who will be taking part in today's panel. We have representatives from the Canadian Society of Hospital Pharmacists, the Canadian Pharmacists Association, Ordre des pharmaciens du Québec, and the National Association of Pharmacy Regulatory Authorities.
I would like to remind the witnesses that you have ten minutes per organization to make your presentations. The committee will hear your presentations first before proceeding to the questions.
Let us begin with Ms. Myrella Roy, executive director of the Canadian Society of Hospital Pharmacists. Welcome.